argenex (NASDAQ:ARGX) Price Target Raised to $1,248.00

argenex (NASDAQ:ARGX) had its price objective lifted by Stifel Nicolaus from $1,028.00 to $1,248.00 in a research report released on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

ARGX has been the subject of a number of other research reports. Bank of America upped their target price on argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Wolfe Research reiterated a “peer perform” rating on shares of argenex in a report on Monday, November 24th. Guggenheim reissued a “buy” rating and set a $1,070.00 target price on shares of argenex in a report on Thursday, September 18th. Finally, TD Cowen raised their price target on shares of argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, argenex currently has an average rating of “Moderate Buy” and a consensus target price of $968.83.

argenex Trading Down 1.3%

Shares of NASDAQ ARGX opened at $877.94 on Thursday. The company has a market cap of $54.05 billion, a price-to-earnings ratio of 37.70, a PEG ratio of 0.88 and a beta of 0.37. argenex has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a 50-day moving average price of $863.28 and a two-hundred day moving average price of $717.23.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. On average, sell-side analysts predict that argenex will post 3.13 earnings per share for the current year.

Institutional Investors Weigh In On argenex

Large investors have recently modified their holdings of the company. Ameriflex Group Inc. bought a new stake in argenex during the third quarter valued at $32,000. Sunbelt Securities Inc. acquired a new position in shares of argenex in the 3rd quarter valued at about $36,000. WPG Advisers LLC bought a new stake in shares of argenex during the 1st quarter valued at about $37,000. Brooklyn Investment Group grew its stake in argenex by 102.7% during the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after purchasing an additional 38 shares during the period. Finally, Bessemer Group Inc. increased its holdings in argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after purchasing an additional 47 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.